<p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS - 獲取免費報告）的股票在覆蓋該股票的五家經紀公司中被評為 “適度買入”，MarketBeat Ratings 報告稱。一位股票研究分析師給予該股票賣出評級，四位分析師給予該公司買入評級。在過去一年中，給予該股票評級的經紀公司平均一年目標價為 13.75 美元。</p>
<p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<p>幾位分析師最近對 CRVS 股票發佈了報告。華爾街禪在 8 月 9 日的報告中將 Corvus Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。巴克萊在週一的報告中開始覆蓋 Corvus Pharmaceuticals 的股票。他們對該股票設定了 “增持” 評級和 16.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Corvus Pharmaceuticals 股票的 “賣出（d-）” 評級。</p>
<p><strong>閲讀我們關於 CRVS 的最新報告</strong></p>
<h2>Corvus Pharmaceuticals 股票下跌 4.4%</h2>
<p>CRVS 股票週一開盤價為 6.93 美元。該公司的市值為 5.1635 億美元，市盈率為 -6.86，貝塔值為 0.57。該公司的 50 日簡單移動平均線為 5.83 美元，200 日簡單移動平均線為 4.49 美元。Corvus Pharmaceuticals 的 12 個月低點為 2.54 美元，12 個月高點為 10.00 美元。</p>
<p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近一次公佈財報是在 8 月 7 日。該公司報告本季度每股收益為（0.10）美元，超出市場共識預期的（0.13）美元 0.03 美元。股票研究分析師預測 Corvus Pharmaceuticals 本年度每股收益將為 -0.63。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了該公司的股票。Shelton Wealth Management LLC 在第三季度收購了 Corvus Pharmaceuticals 的新頭寸，價值約 101,000 美元。中國泛海資產管理有限公司在第二季度將其在 Corvus Pharmaceuticals 的持股增加了 20.2%。中國泛海資產管理有限公司現在擁有 15,488 股該公司的股票，價值 62,000 美元，此前在此期間又購買了 2,599 股。Squarepoint Ops LLC 在第二季度將其在 Corvus Pharmaceuticals 的持股增加了 37.0%。Squarepoint Ops LLC 現在擁有 138,462 股該公司的股票，價值 554,000 美元，此前在此期間又購買了 37,430 股。Sender Co &amp; Partners Inc. 在第二季度收購了 Corvus Pharmaceuticals 的新頭寸，價值約 52,000 美元。最後，Perceptive Advisors LLC 在第二季度收購了 Corvus Pharmaceuticals 的新頭寸，價值約 5,754,000 美元。46.64% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Corvus Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，以治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>5 只適合股息增長投資者的折扣機會</li>
<li>Reddit-ChatGPT 的愛情故事結束了嗎？</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>3 只銅股票準備在下一個金屬超級週期中大放異彩</li>
<li>每股收益計算器：如何計算 EPS</li>
<li>Microsoft 365 Premium 標誌着 AI 貨幣化的下一個階段</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦，現在就買入，以便在更廣泛的市場注意到之前... 而 Corvus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

Corvus制藥

<p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS）獲得了五家券商的 “適度買入” 平均評級。一位分析師將其評級為賣出，而四位分析師則將其評級為買入。平均目標價為 13.75 美元。最近的報告包括巴克萊將其評級設定為 “增持”，目標價為 16.00 美元，以及韋斯評級維持 “賣出” 評級。該股票開盤價為 6.93 美元，市值為 5.1635 億美元。機構投資者持有該股票的 46.64%。Corvus 專注於開發免疫調節劑以治療各種疾病</p>

<p>Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been assigned an average rating of &#34;Moderate Buy&#34; from the five brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $13.75.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS - 獲取免費報告）的股票在覆蓋該股票的五家經紀公司中被評為 “適度買入”，MarketBeat Ratings 報告稱。一位股票研究分析師給予該股票賣出評級，四位分析師給予該公司買入評級。在過去一年中，給予該股票評級的經紀公司平均一年目標價為 13.75 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several analysts recently issued reports on CRVS shares. Wall Street Zen raised shares of Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 9th. Barclays began coverage on shares of Corvus Pharmaceuticals in a report on Monday. They set an &#34;overweight&#34; rating and a $16.00 target price on the stock. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>幾位分析師最近對 CRVS 股票發佈了報告。華爾街禪在 8 月 9 日的報告中將 Corvus Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。巴克萊在週一的報告中開始覆蓋 Corvus Pharmaceuticals 的股票。他們對該股票設定了 “增持” 評級和 16.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Corvus Pharmaceuticals 股票的 “賣出（d-）” 評級。</p>
</div><p><strong>Read Our Latest Report on CRVS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CRVS 的最新報告</strong></p>
</div><h2>Corvus Pharmaceuticals Trading Down 4.4%</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 股票下跌 4.4%</h2>
</div><p>Shares of CRVS stock opened at $6.93 on Monday. The company has a market capitalization of $516.35 million, a PE ratio of -6.86 and a beta of 0.57. The firm has a fifty day simple moving average of $5.83 and a 200-day simple moving average of $4.49. Corvus Pharmaceuticals has a twelve month low of $2.54 and a twelve month high of $10.00.</p>
<div class="lb-trans"><p>CRVS 股票週一開盤價為 6.93 美元。該公司的市值為 5.1635 億美元，市盈率為 -6.86，貝塔值為 0.57。該公司的 50 日簡單移動平均線為 5.83 美元，200 日簡單移動平均線為 4.49 美元。Corvus Pharmaceuticals 的 12 個月低點為 2.54 美元，12 個月高點為 10.00 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. Equities research analysts predict that Corvus Pharmaceuticals will post -0.63 EPS for the current year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近一次公佈財報是在 8 月 7 日。該公司報告本季度每股收益為（0.10）美元，超出市場共識預期的（0.13）美元 0.03 美元。股票研究分析師預測 Corvus Pharmaceuticals 本年度每股收益將為 -0.63。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Shelton Wealth Management LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $101,000. China Universal Asset Management Co. Ltd. increased its stake in Corvus Pharmaceuticals by 20.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company's stock valued at $62,000 after buying an additional 2,599 shares during the period. Squarepoint Ops LLC increased its stake in Corvus Pharmaceuticals by 37.0% during the 2nd quarter. Squarepoint Ops LLC now owns 138,462 shares of the company's stock valued at $554,000 after buying an additional 37,430 shares during the period. Sender Co &amp; Partners Inc. acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $52,000. Finally, Perceptive Advisors LLC acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $5,754,000. 46.64% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了該公司的股票。Shelton Wealth Management LLC 在第三季度收購了 Corvus Pharmaceuticals 的新頭寸，價值約 101,000 美元。中國泛海資產管理有限公司在第二季度將其在 Corvus Pharmaceuticals 的持股增加了 20.2%。中國泛海資產管理有限公司現在擁有 15,488 股該公司的股票，價值 62,000 美元，此前在此期間又購買了 2,599 股。Squarepoint Ops LLC 在第二季度將其在 Corvus Pharmaceuticals 的持股增加了 37.0%。Squarepoint Ops LLC 現在擁有 138,462 股該公司的股票，價值 554,000 美元，此前在此期間又購買了 37,430 股。Sender Co &amp; Partners Inc. 在第二季度收購了 Corvus Pharmaceuticals 的新頭寸，價值約 52,000 美元。最後，Perceptive Advisors LLC 在第二季度收購了 Corvus Pharmaceuticals 的新頭寸，價值約 5,754,000 美元。46.64% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Corvus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，以治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>Is the Reddit-ChatGPT Love Affair Over?</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>3 Copper Stocks Ready to Shine in the Next Metal Supercycle</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>Microsoft 365 Premium Marks the Next Phase of AI Monetization</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Corvus Pharmaceuticals</li>
<li>5 只適合股息增長投資者的折扣機會</li>
<li>Reddit-ChatGPT 的愛情故事結束了嗎？</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>3 只銅股票準備在下一個金屬超級週期中大放異彩</li>
<li>每股收益計算器：如何計算 EPS</li>
<li>Microsoft 365 Premium 標誌着 AI 貨幣化的下一個階段</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JWUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦，現在就買入，以便在更廣泛的市場注意到之前... 而 Corvus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Corvus 製藥公司（NASDAQ:CRVS）被分析師給予 “適度買入” 的平均推薦